Table 2:
Overview of most common (≥5% patient in either arm) grade ≥3 toxicities, at least possibly related to treatment
Adverse event, n (%) | Arm A Bevacizumab + Dasatinib (N=83) |
Arm B Bevacizumab + Placebo (N=38) |
---|---|---|
Hematologic | ||
Lymphopenia | 8 (9.6%) | 1 (2.6%) |
Non-hematologic | ||
Hypertension | 6 (7.2%) | 5 (13.2%) |
Fatigue | 10 (12.0%) | 0 |
Diarrhea | 5 (6.0%) | 0 |
Hypophosphatemia | 12 (14.5%) | 1 (2.6%) |